|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||191.00 - 195.42|
|52 Week Range||181.22 - 262.00|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||20.42|
|Earnings Date||Oct 31, 2023 - Nov 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||236.92|
Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.
Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.
WILMINGTON, Mass., September 26, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™. The platform has the capability to reduce LVV manufacturing timelines for gene and gene-modified cell therapies by up to 60 percent, translating to fewer than seven months compared to traditional manufacturing workflows.